Home >Product >Cephradine compacted/micro
Cephradine compacted/micro
Cephradine compacted/micro
CAS No.:38821-53-3
Molecular Formula:C16H19N3O4S
Molecular Weight:349.41
PRODUCT NAME:Cephradine compacted/micro

Welcome to the world of advanced antibiotic therapy with Cephradine, a trusted and potent medication designed to combat bacterial infections effectively. With its broad spectrum of action and proven track record, Cephradine stands as a reliable choice for healthcare providers and patients alike. Embrace the power of Cephradine to restore health and vitality in the face of bacterial challenges.

What is Cephradine?

Cephradine belongs to the class of first-generation cephalosporin antibiotics. It is formulated to target a wide range of bacterial pathogens responsible for various infections. As a beta-lactam antibiotic, Cephradine disrupts bacterial cell wall synthesis, leading to the eventual death of the harmful bacteria.

How Does Cephradine Work?

Cephradine's mode of action involves inhibiting the enzymes responsible for building bacterial cell walls. By doing so, it weakens the integrity of the cell wall, causing it to rupture and leading to the destruction of the bacteria. This mechanism ensures a rapid and effective response to bacterial infections.

Key Features and Benefits:

1:Broad-Spectrum Activity: Cephradine showcases excellent efficacy against both Gram-positive and Gram-negative bacteria, making it a versatile solution for a wide range of infections.

2:Respiratory Infections: Cephradine is particularly effective in treating respiratory infections, including bronchitis, tonsillitis, and sinusitis, offering relief from troublesome symptoms.

3:Urinary Tract Infections (UTIs): Cephradine helps combat UTIs caused by susceptible bacteria, promoting quick recovery and reducing the risk of complications.

4:Skin and Soft Tissue Infections: From mild to moderate skin infections, Cephradine targets bacteria responsible for cellulitis, wound infections, and other skin-related concerns.

5:Surgical Prophylaxis: Cephradine is widely used as a prophylactic measure before certain surgical procedures to prevent potential infections.

Product Name:

Cefradine

Batch No:

32051704082

Manuf Date:

20 April 2017

LAB Record No.

BPAC04-1704005

Specification:

BP2014

Package Size:

25kg/drum

Batch Size:

857.21Kg

Report Date

03 May 2017

Retest Date:

March 2020

PARAMETER

SPECIFICATIONS

RESULTS

Anpearance

 

white or slightly yellow,

 hygroscopic powder

 

Complies

Identification

 

The IR spectrum confirm to 

that of reference standard

 

Complies

 

 

Appearance of solution

 

less opalescent than 

reference suspension II

 

<reference suspension I

 

The absorbance at 450 nm 

is not greater than 0.60

0.02

 

pH

3.5~6.0

5.1

 

Specific optical rotation

+80.0°~+90.0°

+84.9°

 

 

 

Related substances

(D-dihydrophenylgcine 

NMT 0.25%)

0.01%

(Impurity A NMT 0.25%)

N.D.

(Impurity C NMT 0.25%)

0.04%

Cmpurity D NMT 0.25%)

0.05%

(Impurity E NMT 0.25%)

0.03%

(Impurity F NMT 0.25%)

N.D.

(Impurity G NMT 0.25%)

N.D.

(Any other impurity NMT 0.25%)

0.08%

(Total impurities NMT 2.0%)

0.38%

 

N,N-Dimethylformamide

 

NMT  0.088%

N.D.

 

Acetone

 

NMT  0.5%

0.008%

 

Methylene chloride

 

NMT   0.06%

0.009%

 

Water Content

 

NMT  6.0%

4.1%

 

Sulfated ash

 

NMT  0.2%

<0.1%

 

 

 

 

Assay

 

cefradine : minimum 90.0 per cent

(anhydrous substance)

97.8%

 

cefalexin: maximum 5.0 per cent

(anhydrous substance)

1.2%

 

4'.5-dihydrocefradine: maximum 

2.0 per cent(anhydrous substance)

0.8%

 

sum of the percentage contents of 

cefradine, cefalexin and 4',5'- 

dihydrocefradine :96.0 per cent 

to 102.0 per cent(anhydrous 

substance)

99.8%

Bulk Density

For Information only

0.60g/ml

Tapped Density

For Information only

0.87g/ml

Remarks:

N,N-Dimethylaniline in this process is not utilized  2 0     H

Conclusion

 

The product complies with specification BP2014.

 

 

Have Questions about Arshine Pharma?
Our professional sales team are waiting for your consultation.

INFORMATION

Sign up to receive our weekly newsletter